Market closedNon-fractional

Aquestive Therapeutics/AQST

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Ticker

AQST

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Warren, United States

Employees

135

AQST Metrics

BasicAdvanced
$291M
Market cap
-
P/E ratio
-$0.44
EPS
2.80
Beta
-
Dividend rate
$291M
2.8
6.279
5.733
-93.78
-94.984
-1.91%
-12.74%
39.53%
4.085
-7.98
-7.72
-7.909
10.65%
-31.11%
2.23%
-34.81%

What the Analysts think about AQST

Analyst Ratings

Majority rating from 9 analysts.
Buy

AQST Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-106.66% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12M
-9.09%
Net income
-$13M
58.02%
Profit margin
-106.66%
73.83%

AQST Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 106.48%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.10
-$0.03
-$0.12
-$0.17
-
Expected
-$0.12
-$0.11
-$0.08
-$0.08
-$0.12
Surprise
-15.25%
-73.50%
50.00%
106.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aquestive Therapeutics stock?

Aquestive Therapeutics (AQST) has a market cap of $291M as of July 23, 2024.

What is the P/E ratio for Aquestive Therapeutics stock?

The price to earnings (P/E) ratio for Aquestive Therapeutics (AQST) stock is 0 as of July 23, 2024.

Does Aquestive Therapeutics stock pay dividends?

No, Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Aquestive Therapeutics dividend payment date?

Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders.

What is the beta indicator for Aquestive Therapeutics?

Aquestive Therapeutics (AQST) has a beta rating of 2.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Aquestive Therapeutics stock

Buy or sell Aquestive Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing